Marine Drugs (Dec 2023)

Novel BRICHOS-Related Antimicrobial Peptides from the Marine Worm <i>Heteromastus filiformis</i>: Transcriptome Mining, Synthesis, Biological Activities, and Therapeutic Potential

  • Pavel V. Panteleev,
  • Victoria N. Safronova,
  • Shuting Duan,
  • Alexey S. Komlev,
  • Ilia A. Bolosov,
  • Roman N. Kruglikov,
  • Tatiana I. Kombarova,
  • Olga V. Korobova,
  • Eugenia S. Pereskokova,
  • Alexander I. Borzilov,
  • Igor A. Dyachenko,
  • Olga V. Shamova,
  • Yu Huang,
  • Qiong Shi,
  • Tatiana V. Ovchinnikova

DOI
https://doi.org/10.3390/md21120639
Journal volume & issue
Vol. 21, no. 12
p. 639

Abstract

Read online

Marine polychaetes represent an extremely rich and underexplored source of novel families of antimicrobial peptides (AMPs). The rapid development of next generation sequencing technologies and modern bioinformatics approaches allows us to apply them for characterization of AMP-derived genes and the identification of encoded immune-related peptides with the aid of genome and transcriptome mining. Here, we describe a universal bioinformatic approach based on the conserved BRICHOS domain as a search query for the identification of novel structurally unique AMP families in annelids. In this paper, we report the discovery of 13 novel BRICHOS-related peptides, ranging from 18 to 91 amino acid residues in length, in the cosmopolitan marine worm Heteromastus filiformis with the assistance of transcriptome mining. Two characteristic peptides with a low homology in relation to known AMPs—the α-helical amphiphilic linear peptide, consisting of 28 amino acid residues and designated as HfBRI-28, and the 25-mer β-hairpin peptide, specified as HfBRI-25 and having a unique structure stabilized by two disulfide bonds—were obtained and analyzed as potential antimicrobials. Interestingly, both peptides showed the ability to kill bacteria via membrane damage, but mechanisms of their action and spectra of their activity differed significantly. Being non-cytotoxic towards mammalian cells and stable to proteolysis in the blood serum, HfBRI-25 was selected for further in vivo studies in a lethal murine model of the Escherichia coli infection, where the peptide contributed to the 100% survival rate in animals. A high activity against uropathogenic strains of E. coli (UPEC) as well as a strong ability to kill bacteria within biofilms allow us to consider the novel peptide HfBRI-25 as a promising candidate for the clinical therapy of urinary tract infections (UTI) associated with UPEC.

Keywords